Genital human Papillomavirus infection in patients with autoimmune inflammatory diseases

Joint Bone Spine

Volumn 78, Issue 5, 2011, Pages 460-465

  Aubin, François ^a,b   Martin, Mickaël ^b   Puzenat, Eve ^b   Magy Bertrand, Nadine ^b   Segondy, Michel ^c   Riethmuller, Didier ^a,b   Wendling, Daniel ^b  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Autoimmunity; Biologics; Human Papillomavirus; Immunosuppression; Lupus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; ORAL CONTRACEPTIVE AGENT; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VIRUS ANTIGEN; VIRUS PROTEIN; WART VIRUS VACCINE;

AUTOIMMUNE DISEASE; CANCER INVASION; CELL PROLIFERATION; CIRCUMCISION; COLPOSCOPY; CONDOM; CONDYLOMA ACUMINATUM; CYTOKINE PRODUCTION; CYTOLYSIS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EDUCATIONAL STATUS; GENITAL TRACT INFECTION; GRAFT RECIPIENT; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; LANGERHANS CELL; MASS IMMUNIZATION; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; RHEUMATOID ARTHRITIS; SCREENING TEST; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX TUMOR; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION;

AUTOIMMUNE DISEASES; CONDYLOMATA ACUMINATA; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOCOMPROMISED HOST; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS;

EID: 80053455264     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.03.002     Document Type: Short Survey

References (56)

1. Muñoz N., Bosch F.X., de Sanjosé S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
2. Rodríguez A.C., Schiffman M., Herrero R., et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008, 100:513-517.
3. Grulich A.E., van Leeuwen M.T., Falster M.O., et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370:59-67.
4. Chaturvedi A.K., Madeleine M.M., Biggar R.J., et al. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009, 101:1120-1130.
5. Giuliano A.R., Tortolero-Luna G., Ferrer E., et al. Epidemiology of human papillomavirus infections in men, cancers other than cervical and benign conditions. Vaccine 2008, 26:K17-K28.
6. De Vuyst H., Clifford G.M., Nascimento M.C., et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus, a meta-analysis. Int J Cancer 2009, 124:1626-1636.
7. Einstein M.H., Schiller J.T., Viscidi R.P., et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009, 9:347-356.
8. Leong C.M., Doorbar J., Nindl I., et al. Loss of epidermal Langerhans cells occurs in human papillomavirus alpha, gamma, and mu but not beta genus infections. J Invest Dermatol 2010, 130:472-480.
9. Cordano P., Gillan V., Bratlie S., et al. The E6E7 oncoproteins of cutaneous human papillomavirus type 38 interfere with the interferon pathway. Virology 2008, 377:408-418.
10. Georgopoulos N.T., Proffitt J.L., Blair G.E. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene 2000, 19:4930-4935.
11. Daud I.I., Scott M.E., Ma Y., et al. Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int J Cancer 2011, 128:879-886.
12. Hasan U.A., Bates E., Takeshita F., et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007, 178:3186-3197.
13. Mota F., Rayment N., Chong S., et al. The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium. Clin Exp Immunol 1999, 116:33-40.
14. Basile J.R., Zacny V., Münger K. The cytokines tumor necrosis factor-alpha (TNF-alpha) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein. J Biol Chem 2001, 276:22522-22528.
15. Steele J.C., Mann C.H., Rookes S., et al. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer 2005, 93:248-259.
16. Giannini S.L., Al-Saleh W., Piron H., et al. Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immunol 1998, 113:183-189.
17. Xu Y., Zhu K.J., Zhu N., et al. Expression of Foxp3+CD4+CD25+ regulatory T cells and Th1/Th2 Tc1/Tc2 profiles in the peripheral blood of patients with condyloma acuminatum. Clin Exp Dermatol 2009, 34:229-235.
18. Carter J.J., Koutsky L.A., Hughes J.P., et al. Comparison of human papillomavirus type 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000, 181:1911-1919.
19. Tam L.S., Chan A.Y., Chan P.K., et al. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus. Arthritis Rheum 2004, 50:3619-3625.
20. Klumb E.M., Pinto A., Jesus G., et al. Are women with lupus at higher risk of HPV infection?. Lupus 2010, 19:1485-1491.
21. Nath R., Mant C., Luxton J., et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum 2007, 57:619-625.
22. Tam L.S., Chan P.K., Ho S.C., et al. Natural history of cervical papilloma virus infection in systemic lupus erythematosus - a prospective cohort study. J Rheumatol 2010, 37:330-340.
23. Cibere J., Sibley J., Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001, 10:394-400.
24. Ognevoski V.M., Marder W., Somers E.C., et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004, 31:1763-1767.
25. Blumenfeld Z., Lorber M., Yoffe N., et al. Systemic lupus erythematosus: predisposition for uterine cervical dysplasia. Lupus 1994, 3:59-61.
26. Berthier S., Mougin C., Vercherin P., et al. Does a particular risk associated with papillomavirus infections exist in women with lupus? [Article in French]. Rev Med Interne 1999, 20:128-132.
27. Dhar J.P., Kmak D., Bhan R., et al. Abnormal cervicovaginal cytology in women with lupus: a retrospective cohort study. Gynecol Oncol 2001, 82:4-6.
28. Bernatsky S., Ramsey-Goldman R., Gordon C., et al. Factors associated with abnormal Pap results in systemic lupus erythematosus. Rheumatology (Oxford) 2004, 43:1386-1389.
29. Cirpan T, Guliyeva A, Onder G, et al. Comparison of human papillomavirus testing and cervical cytology with colposcopic examination and biopsy in cervical cancer screening in a cohort of patients with Sjögren's syndrome. Eur J Gynaecol Oncol 200;28:302-6.
30. Rojo Contreras W., Montoya Fuentes H., Gámez Nava J.I., et al. Prevalence and cervical human papillomavirus associated factors in patients with rheumatoid arthritis [Article in Spanish]. Ginecol Obstet Mex 2008, 76:9-17.
31. Bernatsky S., Hudson M., Pope J., et al. Reports of abnormal cervical cancer screening tests in systemic sclerosis. Rheumatology (Oxford) 2009, 48:149-151.
32. Paternoster D.M., Cester M., Resente C., et al. Human papillomavirus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant Proc 2008, 40:1877-1880.
33. Sasadeusz J., Kelly H., Szer J., et al. Abnormal cervical cytology in bone marrow transplant recipients. Bone Marrow Transplant 2001, 28:393-397.
34. Savani B.N., Stratton P., Shenoy A., et al. Increased risk of cervical dysplasia in long-term survivors of allogenic stem cell transplantation - implications for screening and HPV vaccination. Biol Blood Marrow Transplant 2008, 14:1072-1075.
35. Ko M.J., Chu C.Y. Disseminated human papillomavirus type 11 infection in a patient with pemphigus vulgaris: confirmed by DNA analysis. J Am Acad Dermatol 2004, 51:S190-S193.
36. Blazek C., Ghassemi A., Megahed M. HPV-associated carcinoma of the buccal mucosa in a female patient with cicatricial mucosal pemphigoid [Article in German]. Hautarzt 2007, 58:388-390.
37. von Krogh G., Dahlman-Ghozlan K., Syrjänen S. Potential human papillomavirus reactivation following topical corticosteroid therapy of genital lichen sclerosus and erosive lichen planus. J Eur Acad Dermatol Venereol 2002, 16:130-133.
38. Domm S., Cinatl J., Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008, 159:1217-1228.
39. Kim S.Y., Solomon D.H. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 2010, 6:165-174.
40. Shale M.J., Seow C.H., Coffin C.S., et al. Chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010, 31:20-34.
41. Antoniou C., Kosmadaki M.G., Stratigos A.J., Genital HPV, et al. lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology 2008, 216:364-365.
42. Somasekar A., Alcolado R. Genital condylomata in a patient receiving infliximab for Crohn's disease. Postgrad Med J 2004, 80:358-359.
43. Ostor A.G. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993, 12:186-192.
44. Melnikow J., Nuovo J., Willan A.R., et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998, 92:727-735.
45. Liaw K.L., Glass A.G., Manos M.M., et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999, 91:954-960.
46. Mosca M., Tani C., Aringer M., et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010, 69:1269-1274.
47. Bertsias G.K., Salmon J.E., Boumpas D.T. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis 2010, 69:1603-1611.
48. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001, 11:598-603.
49. Gray R.H., Serwadda D., Kong X., et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai Uganda. J Infect Dis 2010, 201:1455-1462.
50. Hernandez B.Y., Shvetsov Y.B., Goodman M.T., et al. Reduced clearance of penile human papillomavirus infection in uncircumcised men. J Infect Dis 2010, 201:1340-1343.
51. Aubin F., Prétet J.L., Jacquard A.C., et al. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis 2008, 47:610-615.
52. Dillner J., Kjaer S.K., et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010, 341:c3493. FUTURE I/II Study Group.
53. Fairley C.K., Hocking J.S., Gurrin L.C., et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009, 85:499-502.
54. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
55. Anaes Conduite à tenir devant une patiente ayant un frottis cervico-utérin anormal. Actualisation. Recommandations pour la pratique clinique 2002, Anaes, Paris.
56. Nieto K., Gissmann L., Schädlich L. Human Papillomavirus-specific immune therapy: failure and hope. Antivir Ther 2010, 15:951-957.